Study summary

CAR T-cell therapy produced responses in 95% of people with heavily treated marginal zone lymphoma

TRANSCEND FL, marginal zone cohort · 67 treated, phase 2 · Published February 2026, The Lancet; FDA approved December 2025

What was tested

Lisocabtagene maraleucel (liso-cel), a one-time CAR T-cell therapy aimed at CD19, for relapsed or refractory marginal zone lymphoma after at least two earlier treatments.

What they found

• Overall response rate was 95%; people had a median of 3 earlier treatments.
• Severe cytokine release syndrome and neurological events each occurred in 4%, with no grade 4-5 events.
• Severe infections occurred in 16%.

What it means

The first CAR T-cell therapy approved for marginal zone lymphoma.